AstraZeneca ((AZN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca has recently completed a significant clinical study titled ‘A Multicenter, Single-arm, Open-label, Post-Authorization, Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants With Severe Asthma Including Several Under-Studied Populations in the United States (PASSAGE).’ The study aimed to assess the effectiveness and safety of tezepelumab, a treatment for severe asthma, particularly focusing on under-studied populations in the U.S.
The intervention tested in this study is tezepelumab, an experimental drug administered via subcutaneous injection. Participants received 210 mg of tezepelumab every four weeks over a 48-week period. The purpose of this treatment is to manage severe asthma symptoms.
The study followed an interventional design with a single-group assignment. There was no allocation or masking involved, meaning all participants received the treatment, and both researchers and participants were aware of the treatment being administered. The primary purpose of the study was treatment-focused.
Key dates for the study include its start on March 17, 2022, and the last update submitted on October 13, 2025. These dates mark the study’s progression from initiation to its most recent update, highlighting the timeline of data collection and analysis.
The completion of this study could have notable implications for AstraZeneca’s stock performance and investor sentiment. As tezepelumab targets a significant market need in asthma treatment, positive results could enhance AstraZeneca’s competitive position in the pharmaceutical industry, potentially influencing stock prices positively.
The study is completed, with further details available on the ClinicalTrials portal.